1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Leqembi |
| structure | File | |
| classes | List of String, delimiter: , | Anti-amyloid beta (Aβ) monoclonal antibody • targets protofibrils |
| mechanism | String | |
| uses | String | Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 |
| starting_dose | String | 10 mg/kg IV every 2 weeks |
| preparations | String | 200 mg/2 mL, 500 mg/5 mL vials for IV infusion |
| fda_max | String | 10 mg/kg q2w |
| pill_id | Text | |
| routes | List of String, delimiter: , | IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting |
| onset | String | Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) |
| duration | String | Ongoing dosing |
| halflife | String | ~5-7 days |
| bioavailability | String | 100% (IV) |
| pregnancy | String | Limited data |
| legal | String | Rx; REMS-like program for ARIA monitoring |
